Glycopegylated factor IX
View Patent ↗The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
1. A Factor IX peptide conjugate comprising a glycosyl linking group attached to an amino acid residue of a Factor IX peptide comprising SEQ ID NO: 1, wherein the glycosyl linking group is attached to an amino acid of SEQ ID NO: 1 selected from the group consisting of Asn 157 and Asn 167, the glycosyl linking group comprising a modified sialyl residue having the formula:
wherein
R 2 is H, CH 2 OR 7 , COOR 7 or OR 7
wherein
R 7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;
R 3 and R 4 are members independently selected from H, substituted or unsubstituted alkyl, OR 8 , NHC(O)R 9
wherein
R 8 and R 9 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid;
L a is a linker selected from a bond, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl′
R 16 and R 17 are independently selected polymeric arms;
X 2 and X 4 are independently selected linkage fragments joining polymeric moieties R 16 and R 17 to C; and
X 5 is a non-reactive group.
2. The Factor IX peptide conjugate according to claim 1 , wherein the moiety:
has a formula that is a member selected from:
wherein
Q is selected from H and substituted or unsubstituted C 1 -C 6 alkyl;
e and f are integers independently selected from 1 to 2500; and
q is an integer from 0 to 20.
3. The Factor IX peptide conjugate according to claim 2 , wherein said moiety has a formula that is a member selected from:
wherein
Q is selected from H and substituted or unsubstituted C 1 -C 6 alkyl;
e, f and f′ are integers independently selected from 1 to 2500; and
q and q′ are integers independently selected from 1 to 20.
4. The Factor IX peptide conjugate according to claim 1 , wherein said glycosyl linking group has a formula selected from:
5. The Factor IX peptide conjugate according to claim 4 , wherein said glycosyl linking group has the formula:
6. The Factor IX peptide conjugate according to claim 5 , wherein said glycosyl linking group attached to said amino acid residue has the formula:
wherein
AA is said amino acid residue of said peptide, and
wherein
said amino acid is selected from the group consisting of Asn 157 and Asn 167.
7. The Factor IX peptide conjugate according to claim 1 , wherein said peptide comprises at least one glycosyl linking group comprising a substructure having the formula:
wherein
R 15 is said modified sialyl residue; and
p is an integer from 1 to 10.
8. The Factor IX peptide according to claim 7 , wherein said at least one glycosyl linking group attached to an amino acid of said peptide has a formula selected from:
and combinations thereof
wherein
AA is said amino acid residue of said peptide;
t is an integer equal to 0 or 1;
p is an integer from 1 to 10; and
R 15′ is a member selected from H, OH, sialic acid, said modified sialyl residue and Sia-Sia p
wherein
Sia p is said modified sialyl residue,
wherein at least one R 15′ is selected from said modified sialyl residue and Sia-Sia p .
9. A pharmaceutical formulation comprising the Factor IX peptide conjugate of claim 1 , and a pharmaceutically acceptable carrier.
10. A Factor IX peptide conjugate comprising a glycosyl linking group attached to an amino acid residue of a Factor IX peptide comprising SEQ ID NO:1, wherein the glycosyl linking group is attached to an amino acid of SEQ ID NO:1 selected from the group consisting of Asn 157 and Asn 167, the glycosyl linking group comprising a modified sialyl residue having the formula:
wherein
R 2 is H, CH 2 OR 7 , COOR 7 , COO − or OR 7
wherein
R 7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;
R 3 and R 4 are members independently selected from H, substituted or unsubstituted alkyl, OR 8 , NHC(O)R 9
wherein
R 8 and R 9 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid;
s is an integer from 1 to 20;
f is an integer from 1 to 2500; and
Q is a member selected from H and substituted or unsubstituted C 1 -C 6 alkyl.
11. The Factor IX peptide conjugate according to claim 10 , wherein said modified sialyl residue has the formula:
12. The Factor IX peptide conjugate according to claim 11 , wherein Q is selected from H and CH 3 .
13. The Factor IX peptide conjugate according to claim 10 , wherein said peptide comprises at least one glycosyl linking group comprising a substructure having the formula:
wherein
R 15 is said modified sialyl residue; and
p is an integer from 1 to 10.
14. The Factor IX peptide conjugate according to claim 13 , wherein said at least one glycosyl linking group attached to an amino acid of said peptide has a formula selected from:
and combinations thereof
wherein
AA is said amino acid residue of said peptide;
t is an integer equal to 0 or 1;
p is an integer from 1 to 10; and
R 15′ is a member selected from H, OH, sialic acid, said modified sialyl residue and Sia-Sia p
wherein
Sia p is said modified sialyl residue,
wherein at least one R 15′ is selected from said modified sialyl residue and Sia-Sia p .
15. The peptide conjugate according to claim 10 , wherein said glycosyl linking group comprises the formula:
in which
b is 0 or 1.
16. The peptide conjugate according to claim 15 , wherein s is 1; and f is an integer from about 200 to about 300.
17. A pharmaceutical formulation comprising the Factor IX peptide conjugate according to claim 10 , and a pharmaceutically acceptable carrier.
18. The Factor IX peptide conjugate according to claim 1 , wherein
R 2 is COOR 7 ,
wherein R 7 is H;
R 3 is H;
R 4 is OR 8 , wherein
R 8 is H;
L a is NHC(O)CH 2 NHC(O)OCH 2
X 5 is H; and
R 16 and R 17 are poly(ethylene glycol) having a total molecular weight of about 40 kDa.
19. A pharmaceutical formulation comprising the Factor IX peptide conjugate according to claim 10 , and a pharmaceutically acceptable carrier.
20. The Factor IX peptide conjugate according to claim 1 , wherein
R 2 is COOR 7 ,
wherein R 7 is H;
R 3 is H;
R 4 is OR 8 , wherein
R 8 is H;
L a is NHC(O)CH 2 NHC(O)OCH 2
X 5 is H; and
R 16 and R 17 are poly(ethylene glycol) having a total molecular weight of about 40 kDa.